Reuters logo
BRIEF-Can-Fite Biopharma, co's unit Ophthalix Inc and Wize Pharma enters into an agreement and plan of merger
May 22, 2017 / 10:55 AM / 5 months ago

BRIEF-Can-Fite Biopharma, co's unit Ophthalix Inc and Wize Pharma enters into an agreement and plan of merger

May 22 (Reuters) - Can Fite Biopharma Ltd:

* Can-Fite Biopharma Ltd - co’s unit Ophthalix Inc, a unit of Ophthalix Bufiduck Ltd and Wize Pharma Ltd entered into an agreement and plan of merger

* Can-Fite Biopharma Ltd -each outstanding ordinary share of Wize will be converted into the right to receive 5.3681 of Ophthalix’s common stock

* Can-Fite Biopharma Ltd - Ophthalix Bufiduck Ltd will merge with and into Wize, with Wize becoming a wholly-owned subsidiary of Ophthalix

* Can-Fite Biopharma - Wize shareholders are expected to own about 90pct of Ophthalix while Ophthalix stockholders are expected to own remaining about 10pct Source text: (bit.ly/2r8Goj7) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below